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Abstract 
A synthesis of novel bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles), bis(4H-chromene-3-carbonitriles) 
and bis(dihydropyrano[3,2-c]chromenes), which are linked to aliphatic spacers via amide linkages was 
achieved via multicomponent reactions (MCR) of the appropriate bis-aldehyde with two equivalents of both of 
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Introduction 
 
The amide group is one of the most popular and reliable functionalities in organic chemistry. Amides are a 
core structural unit in the skeleton of proteins and frequently occur in a wide variety of molecules, such as 
natural products and biologically active compounds including pharmaceuticals (e.g., the marketed drugs 




Figure 1. Chemical structures of some amidic marketed drugs. 
 
The favorable properties of amide groups, such as high polarity, stability and conformational diversity 
stimulated authors to search for improved methods for the synthesis of novel amide-based molecules.1–7 The 
Michael addition reaction represents a powerful synthetic approach in the area of synthetic heterocyclic 
chemistry. Its applications in pharmaceutical research and drug discovery have been the subject of many 
publications in the last decades.8–11 On the other hand, MCRs are efficient synthetic tools for one-pot 
syntheses of complex organic molecules. MCRs have the advantages of being eco-friendly and intrinsically 
atom-economical reaction.12–14 This has inspired many advances in the design and implementation for the 
construction of diverse heterocyclic scaffolds.15–18 Pyrans constitute an important class of biologically active 
natural and synthetic products. Pyrans and their fused analogues especially, pyrano[2,3-c]pyrazole, chromene 
and pyrano[3,2-c]chromenes play a fundamental role in bioorganic chemistry due to their diverse biological 
applications including anticancer, antiviral and anti-inflammatory activities.19–22 Furthermore, the presence of 
more than one active moiety in the molecule is believed to alter positively the activity for the intended 
application. In the last decade, we reported extensively on the Michael addition reaction23–26 as well as the 
chemistry of bis-(heterocycles) whose heterocyclic moieties were linked via different aliphatic and aromatic 
spacers.8,24,26–33 In continuation of the aforementioned effort, we report herein, the synthesis of new bis(1,4-
dihydropyrano[2,3-c]pyrazole-5-carbonitrile), bis(4H-chromene-3-carbonitrile) and bis(dihydropyrano[3,2-
c]chromene) containing molecules which are linked to aliphatic spacers by amide linkages via a MCR 
procedure aiming at increased biocompatibility for the application as bioactive agents. 
 
 
Results and Discussion 
 
Our first approach to synthesize the bis(fused dihydropyrans) 8-10 included first the synthesis of 
dihydropyrano[2,3-c]pyrazole 5, tetrahydro-4H-chromene 6 and dihydropyrano[3,2-c]chromene 7, each 
bearing a 2-hydroxylphenyl group at the position 4.34–37 These compounds can then undergo simple bis-
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alkylation reaction with bis(2-chloroacetamide) 4a in basic medium to give the target molecules 8-10. The TLC 
of the reaction mixtures indicates the presence of a mixture of products which could unfortunately not be 




Scheme 1. Attempted bis-alkylation of 4-(2-hydroxyphenyl)-substituted dihydropyrano[2,3-c]pyrazole 5, 
tetrahydro-4H-chromene 6 and dihydropyrano[3,2-c]chromene 7 with bis(2-chloroacetamide) 4. 
 
In the second approach, the bis-aldehyde 12a containing an amide linkage was prepared following the 
reported methods described by our group8,38–41 via the reaction of the potassium salt of the salicylaldehyde 11 




Scheme 2. Synthesis of bis-aldehyde 12a. 
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A subsequent MCR of 12a with two equivalents of both of malononitrile 13 and 5-methyl-2,4-dihydro-3H-
pyrazol-3-one 14 or dimedone 15 in ethanol heated at reflux in the presence of piperidine gave bis(1,4-
dihydropyrano[2,3-c]pyrazole-5-carbonitrile) 8a and bis(4H-chromene-3-carbonitrile) 9a in 82 and 65% yields, 
respectively. Similarly, the MCR of compound 12a with malononitrile and 4-hydroxycoumarin 16 in pyridine 




Scheme 3. Synthesis of bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) 8a, bis(4H-chromene-3-
carbonitrile) 9a and bis(dihydropyrano[3,2-c]chromene) 10a. 
 
The structure of compounds 8a-10a were supported by their elemental analysis and spectral data. Thus, IR 
spectrum of compound 8a indicated the presence of primary amino groups at ν 3348 and 3310 cm-1, and a 
cyano group at ν 2191 cm-1. The carbonyl group appeared as a broad band at ν 1668 cm-1. The 1H NMR 
spectrum indicated the presence of the pyran-H4 as singlet signal at δH 5.25. Moreover, the pyrazole methyl, 
and the methylene groups, OCH2 and NCH2, were featured as three signals at δH 1.79, 4.47 and 3.29, 
respectively. 
The IR spectra of compound 9a revealed the presence of primary amino groups by absorptions at ν 3487 
and 3410 cm-1 in addition to the cyano and the carbonyl groups at ν 2175 and 1674 cm-1, respectively. The 1H 
NMR spectrum of compound 9a showed the presence of two singlets integrated by 12 protons at δH 0.97 and 
1.01 assigned to four CH3 groups. In addition, it showed a singlet signal at 4.76 ppm assigned to the pyran-H4. 
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The IR spectrum of compound 10a showed the presence of primary amino groups by absorptions at ν 
3325 and 3279 cm-1. In addition, it revealed the cyano band at ν 2184 cm-1. The carbonyl groups showed a 
broad band at 1671 cm-1. The 1H NMR spectrum of 10a showed the presence of the pyran-H4 as a singlet 
signal at δH 5.02. It is worthy to note that compounds 9a and 10a featured the methylene ether linkage OCH2 
as a multiplet signal at δH 4.44–4.59, although their precursor 12a exhibits a singlet for these protons at δH 
4.63. This may be attributed to the generation of stereogenic centers (in the dihydropyran rings) in the 
products, which are close enough to the diastereotopic CH2 protons. All other protons were seen at the 
expected chemical shifts and integral values (see Experimental Section and Supporting Information). 
To extend the scope of these MCRs, a series of bis-aldehydes 12a-h containing amide linkages have been 
prepared by the reaction of the potassium salt of appropriate hydroxybenzaldehydes 11a-c with the 
corresponding bis(2-chloroacetamides) 4a-d in boiling DMF (Table 1). 
A novel series of bis(dihydropyrano[3,2-c]chromenes) 10a-g were successfully prepared in 87-93% yields 
by MCRs of the appropriate aldehydes 12a-g with malononitrile 13 and 4-hydroxycoumarin 16 in pyridine 
heated at reflux (Table 2). 
 
Table 1. Synthesis of bis-aldehydes 12a-h containing amide linkages 
 
 
Entry X CHO 
(o-, m-, p-) 
Yield 12 
(%) 
1 (CH2)2 o 12a (80) 
2 (CH2)2 m 12b (70) 
3 (CH2)3 o 12c (75) 
4 (CH2)3 m 12d (74) 
5 (CH2)3 p 12e (76) 
6 (CH2)4 o 12f (83) 
7 (CH2)4 m 12g (74) 
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Table 2. Synthesis of bis(dihydropyrano[3,2-c]chromenes) 10a-g 
 
 
Entry X Isomer 
(o-, m-, p-) 
Yields 10 
(%) 
1 (CH2)2 o 10a (90) 
2 (CH2)2 m 10b (73) 
3 (CH2)3 o 10c (87) 
4 (CH2)3 m 10d (89) 
5 (CH2)3 p 10e (91) 
6 (CH2)4 o 10f (93) 
7 (CH2)4 m 10g (87) 
 
Bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles) 8b and 8c could be obtained in 75 and 70% yields, 
respectively, by MCRs of bisaldehydes 12f and 12h with two equivalents of both of malononitrile and 5-
methyl-2,4-dihydro-3H-pyrazol-3-one in ethanol heated at reflux in the presence of piperidine. Also, the 
bis(4H-chromene-3-carbonitrile) 9b was obtained in 82% yield from the reaction of bisaldehyde 12f with two 




Scheme 4. Bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles) 8b and 8c as well as bis(4H-chromene-3-
carbonitrile) 9b. 
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Our study was extended to include the synthesis of bis(dihydropyrano[3,2-c]chromenes) 18a,b which are 
linked to aliphatic spacers via both of amide and ester linkages. Thus, a MCR of 17a,b with two equivalents of 
both of malononitrile and of 4-hydroxycoumarin in pyridine heated at reflux afforded 18a and 18b in 87 and 




Scheme 5. Synthesis of bis(dihydropyrano[3,2-c]chromenes) 18a,b. 
 
On the other hand, attempts to synthesize bis(4H-chromene-3-carbonitriles) 19a,b by a MCR of each of 
17a and 17b with two equivalents of both of malononitrile 13 and dimedone 15 in ethanol in the presence of 
piperidine heated at reflux were unsuccessful. Instead, the reactions gave in both cases ethyl 4-(2-amino-3-
cyano-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-yl)benzoate 20 in 85 and 82% yields, respectively 
(Scheme 6). It is suggested that compound 19a and 19b formed initially and then underwent 
transesterification under the reaction conditions. 
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Scheme 6. Unexpected formation of ethyl 4-(2-amino-3-cyano-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-
chromen-4-yl)benzoate 20 (82-85%). 
 
The synthesis of compounds 8, 9 and 10 proceeded via initial condensation of the bis(aldehydes) 12 with 
two moles of malononitrile 13 to yield bis(arylidenemalononitrile) derivatives I which then react with two moles 
of active methylene compounds 14, 15, or 16 to yield the intermediate Michael adduct II. The intermediate II 
underwent tautomerization to III and subsequent cyclization to give the cyclic intermediates IV. Tautomerization 




Scheme 7. A proposed mechanism for the synthesis of compounds 8, 9 and 10. 
 
The structure of compound 20 was confirmed by spectral as well as elemental analyses. The IR spectrum 
of 20 showed absorption bands at ν 3325, 3387 and 2191 cm-1 due to NH2 and cyano groups, respectively. 
Also, its mass spectrum revealed the expected molecular ion peaks at m/z 366. Moreover, the 1H NMR spectra 
of 20 showed a singlet signal at δH 4.33 attributed to pyran-H4 in addition to triplet and quartet signals at δH 
1.28-1.32 and δH 4.27-4.31 characteristic for the ethoxy group. All other protons appeared at the expected 
chemical shifts and integral values. 
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The bis-aldehydes 17a and 17b containing amide-ester linkages were prepared by the reaction of the 
potassium salt of appropriate 4-formylbenzoic acid 21 with the corresponding bis(2-chloroacetamides) 4a and 




Scheme 8. Synthesis of bisaldehydes 17 a, b. 
 
HMBC characterization 
The chemical structures of compounds 8a, 9b and 10f as representative examples were supported by their 
HMBC spectra. The HMBC spectra revealed correlation peaks in accordance with their proposed structures 




Figure 2. Structures of the possible regioisomers 8a (II), 9b (II) and 10f (II). 
 
The full HMBC spectrum of compound 8a (Figure 3) showed that H4 correlates with each of C3 (δC 135.8 
[F]), CN (δC 121.6 [C]), C6 (δC 161.7 [H]), C7a (δC 155.6 [G]), and C3''' (δC 129.4 [D]) in addition to three 3J-
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Figure 3. HMBC spectrum of compound 8a. 
 
The full HMBC spectrum of compound 9b (Figure 4) revealed characteristic long-range 4J-correlations 
between H4 (δH 4.77) and each of ketonic CO (C5, δC 196.9 [I]), CN (δC 120.6 [I]), C2 (δC 159.2 [G]), C8a (δC 
163.8 [H]), C1''' (δC 154.5 [F]) and C3''' (δC 128.9 [C]) in addition to three 3J-coupling with each of C3 (δC 58.3 
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Figure 4. HMBC spectrum of compound 9b. 
 
Finally, the HMBC spectrum of compound 10f (Figure 5) showed distinct long-range coupling (4J-coupling) 
between H4 (δH 4.96) and each of CO ester (C5 δC 160.4 [I]), CN (δC 120.2 [C]), C2 (δC 155.1 [G]), C10b (δC 158.8 
[H]), C1''' (δC 154.5 [F]) and C3''' (δC 129.7 [D]) besides three 3J-coupling between H4 (δH 4.95) and each of C3 
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We developed an efficient approach for the synthesis of new bis(1,4-dihydropyrano[2,3-c]pyrazole-5-
carbonitrile), bis(4H-chromene-3-carbonitrile) and bis(dihydropyrano[3,2-c]chromene) compounds which are 
linked to aliphatic spacers via amide linkages. Structural assignments for these products were supported by 
the spectral data and elemental analyses. The mild reaction conditions, good yields and easily accessible 






General. Melting points were measured with a Stuart melting point apparatus and are uncorrected. The IR 
spectra were recorded using a FTIR Bruker–vector 22 spectrophotometer as KBr pellets. The 1H and 13C NMR 
spectra were recorded in DMSO–d6 as solvent on Varian Gemini NMR spectrometer at 300 and 75 MHz, 
respectively, using TMS as an internal standard. Chemical shifts were reported as δ values (ppm) while 
couplings constants (J) are measured in hertz (Hz). Mass spectra were recorded with a Shimadzu GCMS–QP–
1000 EX mass spectrometer in EI (70 eV) model. The elemental analyses were performed at the Micro 
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General method for synthesis of compounds 10a–g, 18a and 18b 
A mixture of the appropriate bis-aldehydes (12a-g, 17a or 17b) (1 mmol), malononitrile 13 (2 mmol), and 4-
hydroxy-2H-chromen-2-one 16 (2 mmol) in pyridine (10 mL) was heated at reflux for 2 h. The crude solid was 
collected by filtration and recrystallized from the appropriate solvent. 
 
N,N'-(Ethane-1,2-diyl)bis{2-[2-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromen-4-yl)phenoxy]-
acetamide} (10a). Pale yellow powder (723 mg, 90%), Mp 245-248 °C (dioxane/EtOH), IR (KBr): ν 3325, 3279 
(NH2), 2184 (CN), 1671 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 3.27 (br, 4H, CH2N), 4.44-4.59 (m, 4H, 
OCH2), 5.02 (s, 2H, Pyran H-4), 6.86-7.85 (m, 22H, Ar-H+ 2NH2+2NHCO). 13C NMR (75 MHz, DMSO-d6): δC 30.5, 
38.4, 57.8, 67.9, 104.1, 112.6, 113.3, 116.9, 120.0, 122.2, 122.7, 125.1, 128.8, 129.4, 132.3, 133.2, 152.5, 
154.5, 155.2, 158.5, 160.3, 168.4. MS (EI, 70 eV): m/z (%) 804 [M+]. Anal. Calcd for C44H32N6O10: C, 65.67; H, 
4.01; N, 10.44 found C, 65.90; H, 4.28; N, 10.74. 
N,N'-(Ethane-1,2-diyl)bis{2-[3-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromen-4-yl)phenoxy]-
acetamide} (10b). Pale yellow powder (589 mg, 73%), Mp 195-198 °C (EtOH/dioxane), IR (KBr): ν 3325, 3266 
(NH2), 2159 (CN), 1674 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 3.2 (br, 4H, CH2N), 4.38 (s, 4H, OCH2), 4.43 
(s, 2H, Pyran H-4), 6.82-7.91 (m, 20H, Ar-H+ 2NH2), 8.15 (br, 2H, NHCO). 13C NMR (75 MHz, DMSO-d6): δC 38.6, 
39.5, 58.3, 67.4, 104.2, 113.1, 113.4, 115.2, 117.0, 119.6, 121.3, 122.9, 125.2, 130.0, 133.5, 145.4, 152.6, 
153.9, 158.3, 158.4, 160.0, 168.3. MS (EI, 70 eV): m/z (%) 804 [M+]. Anal. Calcd for C44H32N6O10: C, 65.67; H, 
4.01; N, 10.44 found C, 65.88; H, 4.24; N, 10.23. 
N,N'-(Propane-1,3-diyl)bis{2-[2-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromen-4-yl)phenoxy]-
acetamide} (10c). Pale yellow powder (711 mg, 87%), Mp 252-255 °C (dioxane/EtOH), IR (KBr): ν 3363, 3325 
(NH2), 2198 (CN), 1674 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.40-1.53 (m, 2H, CH2), 2.97-3.01 (m, 4H, 
CH2N), 4.45-4.56 (m, 4H, OCH2), 4.98 (s, 2H, Pyran H-4), 6.91-7.89 (m, 22H, Ar-H+2NH2+2NHCO). 13C NMR (75 
MHz, DMSO-d6): δC 28.9, 30.6, 35.9, 57.3, 67.7, 103.6, 112.3, 112.9, 116.4, 119.4, 121.6, 122.3, 124.4, 128.3, 
129.0, 131.5, 132.6, 152.0, 153.9, 154.9, 158.2, 159.7, 167.4. MS (EI, 70 eV): m/z (%) 818 [M+]. Anal. Calcd for 
C45H34N6O10: C, 66.01; H, 4.19; N, 10.26 found C, 66.27; H, 4.47; N, 10.45. 
N,N'-(Propane-1,3-diyl)bis{2-[3-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromen-4-yl)phenoxy]-
acetamide} (10d). Pale yellow powder (728 mg, 89%), Mp 190-193 °C (EtOH), IR (KBr): 3325, 3179 (NH2), 2191 
(CN), 1674 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.49-1.54 (m, 2H, CH2), 2.99-3.01 (m, 4H, CH2N), 4.39 (s, 
4H, OCH2), 4.43 (s, 2H, Pyran H-4), 6.84-8.07 (m, 20H, Ar-H+2NH2), 8.10 (br, 2H, NHCO). 13C NMR (75 MHz, 
DMSO-d6): δC 29.1, 35.7, 36.9, 57.9, 67.0, 103.8, 112.8, 112.9, 114.7, 116.5, 119.1, 120.8, 122.5, 124.7, 129.6, 
132.9, 144.9, 152.1, 153.5, 157.8, 157.9, 159.5, 167.5. MS (EI, 70 eV): m/z (%) 818 [M+]. Anal. Calcd for 
C45H34N6O10: C, 66.01; H, 4.19; N, 10.26 found C, 65.75; H, 4.41; N, 10.53. 
N,N'-(Propane-1,3-diyl)bis{2-[4-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromen-4-yl)phenoxy]-
acetamide} (10e). Pale yellow powder (744 mg, 91%), Mp 180-182 °C (MeOH), IR (KBr): 3432, 3367 (NH2), 
2199 (CN), 1674 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.47-1.52 (m, 2H, CH2), 2.98-3.12 (m, 4H, CH2N), 
4.40 (s, 4H, OCH2), 4.42 (s, 2H, Pyran H-4), 6.90 (d, 4H, Ar-H, J 8.7 Hz), 7.20 (d, 4H, Ar-H, J 8.7 Hz), 7.33 (s, 4H, 
2NH2), 7.43-7.91 (m, 8H, Ar-H), 8.01 (br, 2H, NHCO). (13C NMR data could not be collected owing to solubility 
issues in hot DMSO-d6).MS (EI, 70 eV): m/z (%) 818 [M+]. Anal. Calcd for C45H34N6O10: C, 66.01; H, 4.19; N, 
10.26 found C, 66.29; H, 4.43; N, 10.05. 
N,N'-(Butane-1,4-diyl)bis{2-[2-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromen-4-yl)phenoxy]-
acetamide} (10f). Pale yellow powder (774 mg, 93%), Mp 266-269 °C (dioxane/EtOH), IR (KBr): ν 3371, 3317 
(NH2), 2191 (CN), 1667 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.25 (br, 4H, CH2), 3.03 (br, 4H, CH2N), 
4.46-4.53 (m, 4H, OCH2), 4.95 (s, 2H, Pyran H-4), 6.88-7.90 (m, 22H, Ar-H+2NH2+2NHCO). 13C NMR (75 MHz, 
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DMSO-d6): δC 26.6, 30.9, 38.3, 57.6, 67.9, 104.2, 112.6, 113.5, 117.0, 120.1, 122.2, 122.9, 125.2, 128.9, 129.7, 
131.9, 133.3, 152.6, 154.5, 155.4, 158.7, 160.4, 167.9. MS (EI, 70 eV): m/z (%) 832 [M+]. Anal. Calcd for 
C46H36N6O10: C, 66.34; H, 4.36; N, 10.09 found C, 66.57; H, 4.17; N, 9.89. 
N,N'-(Butane-1,4-diyl)bis{2-[3-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromen-4-yl)phenoxy]-
acetamide) (10g). Pale yellow powder (724 mg, 87%), Mp 185-188 °C (EtOH), IR (KBr): ν 3163, 3071 (NH2), 
2191 (CN), 1674 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.40 (br, 4H, CH2), 3.10 (br, 4H, CH2N), 4.43 (s, 4H, 
OCH2), 4.44 (s, 2H, Pyran H-4), 6.82-7.92 (m, 20H, Ar-H+2NH2), 8.04 (br, 2H, NHCO). 13C NMR (75 MHz, DMSO-
d6): δC 26.4, 36.8, 37.9, 57.8, 66.9, 103.7, 112.6, 112.8, 114.5, 116.4, 119.0, 120.6, 122.4, 124.5, 129.4, 132.8, 
144.8, 152.0, 153.4, 157.7, 157.8, 159.4, 167.2. MS (EI, 70 eV): m/z (%) 832 [M+]. Anal. Calcd for C46H36N6O10: 
C, 66.34; H, 4.36; N, 10.09 found C, 66.55; H, 4.11; N, 9.90. 
[Ethane-1,2-diylbis(azanediyl)]bis(2-oxoethane-2,1-diyl)bis[4-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano-
[3,2-c]chromen-4-yl)benzoate] (18a). Pale yellow powder (748 mg, 87%), Mp 266-269 °C (EtOH), IR (KBr): ν 
3441, 3359 (NH2), 2199 (CN), 1671 (CO), 1641 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 3.20 (br, 4H, CH2N), 
4.44 (s, 4H, OCH2), 4.70 (s, 2H, Pyran H-4), 7.24-8.0 (m, 20H, Ar-H+2NH2), 8.12 (br, 2H, NHCO). 13C NMR (75 
MHz, DMSO-d6): δC 36.9, 38.5, 57.3, 62.8, 103.1, 112.7, 116.4, 118.8, 120.4, 122.5, 124.6, 127.9, 129.7, 132.9, 
148.7, 152.1, 153.6, 157.9, 159.4, 164.9, 166.8. MS (EI, 70 eV): m/z (%) 860 [M+]. Anal. Calcd for C46H32N6O12: 
C, 64.19; H, 3.75; N, 9.76 found C, 64.45; H, 3.54; N, 9.99. 
[Butane-1,4-diylbis(azanediyl)]bis(2-oxoethane-2,1-diyl)bis[4-(2-amino-3-cyano-5-oxo-4,5-dihydropyrano-
[3,2-c]chromen-4-yl)benzoate] (18b). Pale yellow powder (755 mg, 85%), Mp 205-208 °C (EtOH), IR (KBr): ν 
3449, 3332 (NH2), 2191 (CN), 1628 (CO), 1674 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.43 (br, 4H, CH2), 
3.15 (br, 4H, CH2N), 4.60 (s, 4H, OCH2), 4.70 (s, 2H, Pyran H-4), 7.33-8.01 (m, 22H, Ar-H+2NH2+2NHCO). 13C 
NMR (75 MHz, DMSO-d6): δC 26.4, 36.9, 38.1, 57.3, 62.9, 103.2, 112.8, 116.5, 118.8, 122.5, 124.6, 127.9, 128.1, 
129.7, 130.9, 148.7, 152.2, 153.7, 157.9, 159.4, 164.9, 166.3. MS (EI, 70 eV): m/z (%) 888 [M+]. Anal. Calcd for 
C48H36N6O12: C, 64.86; H, 4.08; N, 9.46 found C, 64.58; H, 3.87; N, 9.76. 
General method for the synthesis of compounds 8a, 8b and 8c. To a mixture of bisaldehyde 12a, 12f or 12h (1 
mmol), malononitrile 13 (0.15 g, 2.2 mmol) and pyrazolone 14 (0.31 g, 2.2 mmol) in absolute ethanol (15 mL) 
was added piperidine (0.2 mL) and the mixture was heated at reflux for 3 h. The crude solid was isolated by 
filtration and recrystallized from the appropriate solvent. 
N,N'-(Ethane-1,2-diyl)bis{2-[2-(6-amino-5-cyano-3-methyl-1,4-dihydropyrano[2,3-c]pyrazol-4-
yl)phenoxy]acetamide} (8a). Pale yellow powder (554.3 mg, 82%), Mp >300 °C (EtOH), IR (KBr): ν 3348, 3310 
(NH2), 2191 (CN), 1668 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.79 (s, 6H, 2CH3), 3.29 (br, 4H, CH2N), 4.47 
(s, 4H, OCH2), 5.25 (s, 2H, Pyran H-4), 6.77 (s, 4H, 2NH2), 6.92-7.20 (m, 8H, Ar-H), 7.87 (br, 2H, NHCO), 12.02 (s, 
2H, NH). 13C NMR (75 MHz, DMSO-d6): δC 10.2, 19.8, 38.7, 67.2, 68.0, 98.2, 112.9, 121.6, 122.2, 128.4, 129.4, 
132.9, 135.8, 155.1, 155.6, 161.7, 168.3. MS (EI, 70 eV): m/z (%) 676 [M+]. Anal. Calcd for C34H32N10O6: C, 
60.35; H, 4.77; N, 20.70 found C, 60.10, H, 4.56; N, 20.99. 
N,N'-(Butane-1,4-diyl)bis{2-[2-(6-amino-5-cyano-3-methyl-1,4-dihydropyrano[2,3-c]pyrazol-4-yl)phenoxy]-
acetamide} (8b). Pale yellow powder (528 mg, 75%), Mp 205-208 °C (EtOH), IR (KBr): ν 3387, 3317 (NH2), 2191 
(CN), 1651 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.43 (br, 4H, CH2), 1.79 (s, 6H, 2CH3), 3.16 (br,4H, CH2N) 
4.48 (s, 4H, OCH2), 5.19 (s, 2H, Pyran H-4), 6.80 (s, 4H, 2NH2), 6.92-7.20 (m, 8H, Ar-H), 7.64 (br, 2H, NHCO), 
12.03 (s, 2H, NH). (13C NMR data could not be collected owing to solubility issues in hot DMSO-d6). 
MS (EI, 70 eV): m/z (%) 704[M+]. Anal. Calcd for C36H36N10O6: C, 61.35; H, 5.15; N, 19.88 found C, 61.65; H, 
5.37; N, 20.17. 
N,N’-(Butane-1,4-diyl)bis{2-[4-(6-amino-5-cyano-3-methyl-1,4-dihydropyrano[2,3-c]pyrazol-4-yl)phenoxy]-
acetamide} (8c). Pale yellow powder (493 mg, 70%), Mp >300 °C (EtOH), IR (KBr): ν 3290, 3208 (NH2), 2183 
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(CN), 1673 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 1.46 (br, 4H, CH2), 1.79 (s, 6H, 2CH3), 3.18 (br, 4H, 
CH2N), 4.67 (s, 4H, OCH2), 5.73 (s, 2H, Pyran H-4), 6.93 (s, 4H, NH2), 7.36 (d, 4H, Ar-H, J 8.4), 8.0 (d, 4H, Ar-H, J 
8.4), 8.16 (br, 2H, NHCO), 12.18 (s, 2H, NH). 13C NMR (75 MHz, DMSO-d6): δC 10.2, 25.7, 27.0, 38.5, 65.9, 63.3, 
97.4, 121.0, 128.3, 128.5, 130.3, 139.5, 150.5, 161.4, 165.6, 168.9. MS (EI, 70 eV): m/z (%) 704 [M+]. Anal. 
Calcd for C36H36N10O6: C, 61.35; H, 5.15; N, 19.88 found C, 61.10; H, 5.36; N, 19.64. 
General methods for synthesis of compounds 9a, 9b and 20 
To a mixture of bisaldehydes 12a, 12f or 17a-b (1 mmol), malononitrile 13 (2.2 mmol), and dimedone 15 (2.2 
mmol) in absolute ethanol (15 mL), piperidine (0.2 mL) was added, and the reaction mixture was heated at 
reflux for3 h. The crude solid was isolated by filtration and recrystallized from the appropriate solvent. 
N,N’-(Ethane-1,2-diyl)bis{2-[2-(2-amino-3-cyano-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-
yl)phenoxy]acetamide} (9a). Pale yellow powder (494 mg, 65%), Mp 200-203 °C (EtOH), IR (KBr): ν 3487, 3410 
(NH2), 2175 (CN), 1674 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 0.97 (s, 6H, 2CH3), 1.01 (s, 6H, 2CH3), 2.12 
(d, 2H, H8, J 16.2), 2.25 (d, 2H, H8, J 16.2), 2.50 (s, 4H, H6), 3.21 (br, 4H, CH2N), 4.46-4.59 (m, 4H, OCH2), 4.76 
(s, 2H, Pyran H-4), 6.87-7.15 (m, 12H, Ar-H+2NH2), 7.85 (br, 2H, NHCO). 13C NMR (75 MHz, DMSO-d6): δC 27.2, 
29.1, 32.2, 38.5, 39.4, 50.4, 58.4, 67.7, 112.3, 113.2, 120.5, 120.6, 122.1, 128.3, 128.7, 133.7, 154.6, 159.0, 
168.5, 196.9. MS (EI, 70 eV): m/z (%) 760 [M+]. Anal. Calcd for C42H44N6O8: C, 66.30; H, 5.83; N, 11.05 found C, 
66.53; H, 6.10; N, 11.29. 
N,N'-(Butane-1,4-diyl)bis{2-[2-(2-amino-3-cyano-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-
yl)phenoxy]acetamide} (9b). Pale yellow powder (646 mg, 82%), Mp 212-215 °C (EtOH), IR (KBr): ν 3363, 3330 
(NH2), 2191 (CN), 1651 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 0.97 (s, 6H, 2CH3), 1.01 (s, 6H, 2CH3), 1.22 
(br, 4H, CH2), 2.14 (d, 2H, H8, J 16.2), 2.29 (d, 2H, H8, J 16.2), 2.50 (s, 4H, H6), 3.06 (br, 4H, CH2N), 4.50-4.62 
(m, 4H, OCH2), 4.76 (s, 2H, Pyran H-4), 6.83-7.15 (m, 12H, Ar-H+2NH2), 7.85 (br, 2H, NHCO). 13C NMR (75 MHz, 
DMSO-d6): δC 26.8, 27.9, 28.3, 31.8, 38.7, 38.9, 50.0, 57.8, 67.2, 111.6, 112.7, 120.0, 121.5, 127.7, 128.4, 133.1, 
154.1, 158.6, 163.3, 167.6, 196.4. MS (EI, 70 eV): m/z (%) 788 [M+]. Anal. Calcd for C44H48N6O8: C, 66.99; H, 
6.13; N, 10.65 found C, 66.71; H, 6.37; N, 10.43. 
2-Amino-4-(4-ethoxyphenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (20). Pale 
yellow powder (311 mg, 85%), Mp 252-255 °C (EtOH), IR (KBr): ν 3367, 3325 (NH2), 2191 (CN), 1712 (CO) cm-1. 
1H NMR (300 MHz, DMSO-d6): δH 0.95 (s, 3H, CH3), 1.03 (s, 3H, CH3), 1.28-1.32 (t, 3H, CH3), 2.12 (d, 2H, H8, J 
16.2), 2.29 (d, 2H, H8, J 16.2), 2.50 (s, 4H, H6), 4.27-4.31 (q, 2H, OCH2), 4.33 (s, 1H, Pyran H-4), 7.06 (s, 2H, 
NH2), 7.31 (d, 2H, Ar-H, J 8.4), 7.89 (d, 2H, Ar-H, J 8.4). 13C NMR (75 MHz, DMSO-d6): δC 14.6, 27.2, 38.8, 32.3, 
36.2, 50.4, 57.9, 61.0, 112.6, 119.9, 128.1, 128.7, 129.8, 150.5, 158.9, 163.3, 165.9, 196.1. MS (EI, 70 eV): m/z 
(%) 366 [M+]. Anal. Calcd for C21H22N2O4: C, 68.84; H, 6.05; N, 7.65 found C, 69.07; H, 6.23; N, 7.89. 
General procedure for the synthesis of compounds 12a-h, 17a and 17b. A solution of the potassium salt of 
salicylaldehyde, m-hydroxybenzaldehyde or p-formylbenzoic acid (10 mmol) (prepared by dissolving aldehydes 
11a-c or p-formylbenzoic acid 21 (10 mmol) in absolute EtOH (5 mL) containing KOH (0.56 g, 10 mmol) and 
evaporating the ethanol under reduced pressure) and the appropriate dichloro compounds 4a-d (5 mmol) in 
DMF (10 mL) was heated at reflux for 5 min. The potassium chloride was separated by filtration, the solvent 
was then removed in vacuo and the remaining residue was washed with water and purified by recrystallization 
from the appropriate solvent to give the corresponding compounds 12a-h, 17a and 17b. 
N,N'-(Ethane-1,2-diyl)bis[2-(2-formylphenoxy)acetamide] (12a). Pale yellow plates (307 mg, 80%), Mp 182-
184 °C (EtOH) (lit. Mp 188-190 °C).42 1H NMR (CDCl3) δH 3.64 (d, 4H, CH2NH), 4.58 (s, 4H, J 5.80, CH2OAr), 6.90–
7.73 (m, 10H, ArH’s, NH), 8.05 (br, 2H, NH), 10.11 (s, 2H, CHO). 
N,N'-(Ethane-1,2-diyl)bis[2-(3-formylphenoxy)acetamide] (12b). Colorless plates (289 mg, 70%), ,Mp 188-190 
°C (H2O), IR (KBr): ν 3363 (NH), 1693 (CO) cm-1. 1H NMR (300 MHz, DMSO-d6): δH 3.26 (br, 4 H, CH2N), 4.55 (s, 4 
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H, OCH2), 7.29-7.54 (m, 8 H, Ar-H), 8.24 (br, 2 H, NH), 9.97 (s, 2 H, CHO). (13C NMR data could not be collected 
owing to solubility issues in hot DMSO-d6). MS (EI, 70 eV): m/z 384 [M+]. Anal. Calcd for C20H20N2O6: C, 62.49; 
H, 5.24; N, 7.29 found C, 62.70; H, 55; N, 7.48. 
N,N'-(Propane-1,3-diyl)bis[2-(2-formylphenoxy)acetamide] (12c). Colorless powder (298.5 mg, 75%), Mp 164-
166 °C (EtOH) (lit Mp 164-165 °C).42 1H NMR (CDCl3) δH 1.83 (t, 2H, J 6.0, CH2CH2NH), 3.42 (q, 4H, J 6.0, CH2NH), 
4.57 (s, 4H, OCH2), 6.90–8.00 (m, 10H, ArH’s, NH), 10.28 (s, 2H, CHO). 
N,N'-(Propane-1,3-diyl)bis[2-(3-formylphenoxy)acetamide] (12d). Colorless powder (294.5 mg, 74%), Mp 
122-124 °C (EtOH), IR (KBr): ν 3348 (NH), 1697 (CO). 1H NMR (300 MHz, DMSO-d6): δΗ 1.57-1.61 (m, 2H, CH2), 
3.10-3.17 (m, 2H, CH2N), 4.57 (s, 4 H, OCH2), 7.29-7.55 (m, 8H, Ar-H), 8.16 (br, 2H, NH), 9.97 (s, 2H, CHO). (13C 
NMR data could not be collected owing to solubility issues in hot DMSO-d6). MS (EI, 70 eV): m/z (%) 398 [M+]. 
Anal. Calcd for C21H22N2O6: C, 63.31; H, 5.57; N, 7.03 found C, 63.09; H, 5.26; N, 7.24. 
N,N'-(Propane-1,3-diyl)bis[2-(4-formylphenoxy)acetamide] (12e). Colorless powder (278.6 mg, 70%), Mp 90-
92 °C (H2O), IR (KBr): ν 3340 (NH), 1687 (CO).  1H NMR (300 MHz, DMSO-d6): δΗ 1.58-1.64 (m, 2H, CH2), 3.12-
3.16 (m, 2H, CH2N), 4.61 (s, 4H, OCH2), 7.15 (d, 4H, Ar-H, J 8.7), 7.90 (d, 4H, Ar-H, J 8.7), 8.21 (br, 2H, NH), 9.90 
(s, 2H, CHO). (13C NMR data could not be collected owing to solubility issues in hot DMSO-d6). MS (EI, 70 eV): 
m/z (%) 398 [M+]. Anal. Calcd for C21H22N2O6: C, 63.31; H, 5.57; N, 7.03 found C, 63.52; H, 5.39; N, 7.30. 
N,N'-(Butane-1,4-diyl)bis[2-(2-formylphenoxy)acetamide] (12f). Colorless powder (342 mg, 83%), Mp 180-
182 °C (EtOH) (lit Mp 178 °C).42 1H NMR (CDCl3) δH 1.73 (br, 4H, CH2CH2NH), 3.40 (q, 4H, J 5.8, CH2NH), 4.58 (s, 
4H, OCH2), 6.90–7.79 (m, 10H, ArH’s, NH), 10.16 (s, 2H, CHO). 
N,N'-(Butane-1,4-diyl)bis[2-(3-formylphenoxy)acetamide] (12g). Colorless powder (305 mg, 74%), Mp 210-
212 °C (EtOH), IR (KBr): ν 3309 (NH), 1693 (CO).  1H NMR (300 MHz, DMSO-d6): 1.41 (br, 4H, CH2), 3.13 (br, 4H, 
CH2N), 4.56 (s, 4H, OCH2), 7.31-7.55 (m, 8H, Ar-H), 8.12 (br, 2H, NH), 9.97 (s, 2H, CHO). (13C NMR data could 
not be collected owing to solubility issues in hot DMSO-d6). 
MS (EI, 70 eV): m/z (%) 412 [M+]. Anal. Calcd for C22H24N2O6: C, 64.07; H, 5.87; N, 6.79 found C, 64.34; H, 6.09; 
N, 6.93. 
N,N'-(Butane-1,4-diyl)bis[2-(4-formylphenoxy)acetamide] (12h). Colorless powder (325.5 mg, 79%), Mp 208-
210 °C (EtOH), IR (KBr): ν 3282 (NH), 1689 (CO).  1H NMR (300 MHz, DMSO-d6): δΗ 1.42 (br, 4H, CH2), 3.11 (br, 
4H, CH2N), 4.60 (s, 4H, OCH2), 7.12-7.15 (d, J 8.1, 4H, Ar-H), 7.85-7.88 (d, J 8.1, 4H, Ar-H), 8.24 (br, 2H, NH), 
9.87 (s, 2H, CHO). (13C NMR data could not be collected owing to solubility issues in hot DMSO-d6). MS (EI, 70 
eV): m/z (%) 412 [M+]. Anal. Calcd for C22H24N2O6: C, 64.07; H, 5.87; N, 6.79 found C, 64.37; H, 6.12; N, 6.90. 
[Ethane-1,2-diylbis(azanediyl)]bis(2-oxoethane-2,1-diyl)bis(4-formylbenzoate) (17a). Colorless powder (343 
mg, 78%), Mp 232-234 °C (EtOH/AcOH), IR (KBr): ν 3325 (NH), 1662 (CO). 1H NMR (300 MHz, DMSO-d6): δΗ 
3.23 (br, 4H, CH2N), 4.75 (s, 4H, OCH2), 8.01-8.04 (d, J 8.7, 4H, Ar-H), 8.20-8.23 (m, 6H, Ar-H +NH), 10.11 (s, 2H, 
CHO). (13C NMR data could not be collected owing to solubility issues in hot DMSO-d6). MS (EI, 70 eV): m/z (%) 
440.12 [M+]. Anal. Calcd for C22H20N2O8: C, 60.00; H, 4.58; N, 6.36 found C, 59.85; H, 4.79; N, 6.52. 
[Butane-1,4-diylbis(azanediyl)]bis(2-oxoethane-2,1-diyl)bis(4-formylbenzoate) (17b). Colorless powder (342 
mg, 73%), Mp 238-240 °C (EtOH/AcOH), IR (KBr): ν 3302 (NH), 1658 (CO). 1H NMR (300 MHz, DMSO-d6): δΗ 
1.44 (br, 4H, CH2), 3.13 (br, 4H, CH2N), 4.74 (s, 4H, OCH2), 8.05-8.07 (d, J 8.1, 4H, Ar-H), 8.13 (br, 2H, NH), 8.20-
8.23 (d, J 8.1, 4H, Ar-H), 10.12 (s, 2H, CHO). (13C NMR data could not be collected owing to solubility issues in 
hot DMSO-d6). MS (EI, 70 eV): m/z (%) 468 [M+]. Anal. Calcd for C24H24N2O8: C, 61.53; H, 5.16; N, 5.98 found C, 
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